Moleculin Biotech Inc (MBRX)

Mar 12, 2026

Moleculin Biotech releases CEO update on leukemia trial - Investing.com India

Mar 12, 2026

Mar 11, 2026

Moleculin Biotech releases CEO update on leukemia trial By Investing.com - Investing.com Nigeria

Mar 11, 2026

Mar 11, 2026

Leukemia trial update: Moleculin CEO explains MIRACLE drug study - Stock Titan

Mar 11, 2026

Mar 06, 2026

Pullback Watch: Will Moleculin Biotech Inc benefit from geopolitical trendsMarket Activity Report & Safe Capital Growth Tips - baoquankhu1.vn

Mar 06, 2026

Mar 03, 2026

Moleculin Announces Closing of up to $16.5 Million Public Offering - Quantisnow

Mar 03, 2026

Mar 01, 2026

Aug Reactions: Will Moleculin Biotech Inc benefit from geopolitical trends2025 Fundamental Recap & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn

Mar 01, 2026

Feb 28, 2026

MBRX Should I Buy - Intellectia AI

Feb 28, 2026

Feb 28, 2026

MBRX PE Ratio & Valuation, Is MBRX Overvalued - Intellectia AI

Feb 28, 2026

Feb 27, 2026

Moleculin Biotech (MBRX) seeks OK for 6.37M warrants, $15.3M proceeds - Stock Titan

Feb 27, 2026

Feb 22, 2026

Why Did MBRX Stock Climb 14% Today? - Stocktwits

Feb 22, 2026

Feb 20, 2026

Moleculin Biotech Inc. (MBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Feb 20, 2026

Feb 20, 2026

Is Moleculin Biotech Inc. forming higher highs and higher lowsJuly 2025 Reactions & Community Trade Idea Sharing Platform - mfd.ru

Feb 20, 2026

Feb 20, 2026

Moleculin Biotech Raises Capital via Inducement Warrant Agreements - TipRanks

Feb 20, 2026

Feb 20, 2026

Why Moleculin Biotech Inc. stock remains on buy listsDollar Strength & Daily Entry Point Trade Alerts - mfd.ru

Feb 20, 2026

Feb 20, 2026

Moleculin Biotech Secures Up To $8.3 Million Via Warrant Exercise; Issues 300% Series H Warrants - TradingView

Feb 20, 2026

Feb 20, 2026

Moleculin Biotech stock plunges after warrant exercise agreement By Investing.com - Investing.com Australia

Feb 20, 2026

Feb 20, 2026

Moleculin Biotech Exercises Warrants for $8.3M - Intellectia AI

Feb 20, 2026

Feb 19, 2026

Moleculin Biotech raises $8.3 million through warrant exercise By Investing.com - Investing.com Canada

Feb 19, 2026

Feb 19, 2026

Moleculin shares slide sharply after warrant exercise deal - MSN

Feb 19, 2026

Feb 19, 2026

Aug Intraday: Can Moleculin Biotech Inc maintain sales growth2025 Price Momentum & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn

Feb 19, 2026

Feb 19, 2026

Moleculin Stock Plunges On $8.3 Million Warrant Exercise - Nasdaq

Feb 19, 2026

Feb 19, 2026

Moleculin Biotech stock plunges after warrant exercise agreement - Investing.com South Africa

Feb 19, 2026

Feb 19, 2026

Moleculin Biotech raises $8.3 million through warrant exercise - Investing.com

Feb 19, 2026

Feb 19, 2026

Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds - The Manila Times

Feb 19, 2026

Feb 19, 2026

Moleculin Biotech, Inc. Announces Agreement for Immediate Exercise of Warrants to Raise Approximately $8.3 Million - Quiver Quantitative

Feb 19, 2026

Feb 19, 2026

Moleculin reports promising early data in pivotal AML treatment trial By Investing.com - Investing.com India

Feb 19, 2026

Feb 18, 2026

Moleculin Biotech Issues New Investor Corporate Presentation - TipRanks

Feb 18, 2026

Feb 18, 2026

Moleculin Biotech (MBRX) Nears Key Milestone in Leukemia Trial P - GuruFocus

Feb 18, 2026

Feb 18, 2026

Moleculin Biotech stock rises as AML drug trial shows promising results - Investing.com Nigeria

Feb 18, 2026

Feb 18, 2026

Moleculin Biotech stock rises as AML drug trial shows promising results By Investing.com - Investing.com Canada

Feb 18, 2026

Feb 18, 2026

Moleculin Reports Positive Progress in MIRACLE AML Trial - TipRanks

Feb 18, 2026

Feb 18, 2026

Moleculin reports promising early data in pivotal AML treatment trial - Investing.com

Feb 18, 2026

Feb 18, 2026

Moleculin reports 40% preliminary CRc in MIRACLE trial; 35 treated, 45-subject unblinding on track - TradingView

Feb 18, 2026

Feb 18, 2026

Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30) - GlobeNewswire

Feb 18, 2026

Feb 18, 2026

Moleculin receives patent allowance in Japan for Annamycin preparation method - Investing.com India

Feb 18, 2026

Feb 18, 2026

Moleculin Biotech Receives Patent Allowance from Japan Patent Office - Intellectia AI

Feb 18, 2026

Feb 17, 2026

Profit Recap: What are Moleculin Biotech Incs earnings expectations2025 Dividend Review & Low Risk High Win Rate Picks - baoquankhu1.vn

Feb 17, 2026

Feb 17, 2026

Moleculin Biotech stock rises after securing key Japanese patent - Investing.com

Feb 17, 2026

Feb 17, 2026

Moleculin Biotech stock rises after securing key Japanese patent By Investing.com - Investing.com India

Feb 17, 2026

Feb 17, 2026

Moleculin Biotech Says Japan Patent Office Issues Notice of Allowance for Patent Covering Annamycin; Shares Rise Pre-Bell - marketscreener.com

Feb 17, 2026

Feb 17, 2026

Moleculin Biotech (MBRX) Gains Japanese Patent Progress for Lipo - GuruFocus

Feb 17, 2026

Feb 17, 2026

Moleculin Gains Japanese Patent Allowance for Annamycin - TipRanks

Feb 17, 2026

Feb 17, 2026

Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin - The Manila Times

Feb 17, 2026

Feb 17, 2026

Moleculin Biotech, Inc. Receives Notice of Allowance for Japanese Patent on Liposomal Annamycin Preparation Methods - Quiver Quantitative

Feb 17, 2026